BOLT (Bolt Biotherapeutics) ROCE %: -68.33% (As of Mar. 2026)


BOLT Bolt Biotherapeutics Inc BOLT
55 GF Score
Price $4.20
GF Value $9.03
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Bolt Biotherapeutics ROCE %?

Bolt Biotherapeutics BOLT -1.87% 55 ROCE % is -68.33% as of Mar. 2026. GuruFocus rates BOLT with a GF Score™ of 55/100 and a GF Value™ of $9.03 (Possible Value Trap). The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Bolt Biotherapeutics's annualized ROCE % for the quarter that ended in Mar. 2026 was -68.33%.

Bolt Biotherapeutics  (NAS:BOLT) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Bolt Biotherapeutics ROCE % Related Terms

Bolt Biotherapeutics ROCE % Historical Data

* Premium members only.

The historical data trend for Bolt Biotherapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bolt Biotherapeutics ROCE % Chart

Bolt Biotherapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial -57.69 -36.78 -44.30 -61.17 -52.44

Bolt Biotherapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -62.10 -54.38 -52.10 -43.37 -68.33
BOLT
55GF Score
Bolt Biotherapeutics Inc BOLT
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bolt Biotherapeutics ROCE % Calculation

Bolt Biotherapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-34.633/( ( (99.632 - 15.856) + (56.748 - 8.435) )/ 2 )
=-34.633/( (83.776+48.313)/ 2 )
=-34.633/66.0445
=-52.44 %

Bolt Biotherapeutics's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-30.404/( ( (56.748 - 8.435) + (48.027 - 7.343) )/ 2 )
=-30.404/( ( 48.313 + 40.684 )/ 2 )
=-30.404/44.4985
=-68.33 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -68.33% mean?
Bolt Biotherapeutics (BOLT) has a ROCE % of -68.33% as of Mar. 2026.
Is Bolt Biotherapeutics' ROCE % too high?
Bolt Biotherapeutics' current ROCE % is -68.33%. Overall, Bolt Biotherapeutics has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Bolt Biotherapeutics' ROCE % compare to BCDA and NCNA?
Bolt Biotherapeutics' ROCE % of -68.33% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Bolt Biotherapeutics's current ROCE % is -68.33%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bolt Biotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Bolt Biotherapeutics (BOLT) is currently considered Possible Value Trap. The stock's GF Value™ is $9.03, compared to a current price of $4.20 — trading 53.5% below its estimated fair value. The current ROCE % is -68.33%. Bolt Biotherapeutics' overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Bolt Biotherapeutics (BOLT), the current ROCE % is -68.33% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bolt Biotherapeutics (BOLT) Overvalued in 2026?

Based on GuruFocus' analysis, Bolt Biotherapeutics stock appears to be undervalued. The current stock price of $4.20 is trading 53.5% below its estimated GF Value™ of $9.03. GuruFocus considers Bolt Biotherapeutics to be Possible Value Trap.

Key valuation signals for BOLT:

  • ROCE %: -68.33%
  • GF Value™: $9.03 vs. price of $4.20 (53.5% below fair value)
  • GF Score™: 55/100 with 4 warning signs

No single metric tells the full story. See the BOLT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bolt Biotherapeutics Business Description

Address 900 Chesapeake Drive, Redwood City, CA, USA, 94063
Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.
55GF Score

Get the complete analysis for BOLT

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.20
Price
$9.03
GF Value